Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV2 mutant-specific T cells and neutralizing antibodies after vaccination and up to 1 year after infection

View ORCID ProfileJennifer R. Richardson, Ralph Götz, Vanessa Mayr, Martin J. Lohse, Hans-Peter Holthoff, Martin Ungerer
doi: https://doi.org/10.1101/2021.09.07.21262725
Jennifer R. Richardson
ISAR Bioscience, Semmelweisstrasse 5, D 82152 Planegg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jennifer R. Richardson
Ralph Götz
ISAR Bioscience, Semmelweisstrasse 5, D 82152 Planegg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanessa Mayr
ISAR Bioscience, Semmelweisstrasse 5, D 82152 Planegg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin J. Lohse
ISAR Bioscience, Semmelweisstrasse 5, D 82152 Planegg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Peter Holthoff
ISAR Bioscience, Semmelweisstrasse 5, D 82152 Planegg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: martin.ungerer@isarbioscience.de hans-peter.holthoff@isarbioscience.de
Martin Ungerer
ISAR Bioscience, Semmelweisstrasse 5, D 82152 Planegg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: martin.ungerer@isarbioscience.de hans-peter.holthoff@isarbioscience.de
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective We investigated blood samples from fully SARS-CoV2-vaccinated subjects and from patients up to one year after infection with SARS-CoV2, and compared short and long term T cell and antibody responses, with a special focus on the recently emerged delta variant (B.1.617.2).

Methods and Results In 23 vaccinated subjects, we documented high anti-SARS-CoV2 spike protein receptor binding domain (RBD) antibody titers. Average virus neutralization by antibodies, assessed as inhibition of ACE2 binding to RBD, was 2.2-fold reduced for delta mutant vs. wt RBD. Specific CD4+ T cell responses as measured using stimulation with peptides representing wt or alpha, beta, gamma and delta variant SARS-CoV2 entire spike proteins by flow cytometric intracellular cytokine staining, did not differ significantly between vaccinees.

One year post infection in one of the earliest SARS-CoV2 populations in the Western world, mean specific antibody titers were lower than in vaccinees; ACE2 binding to delta mutant vs. wt RBD was 1.65-fold reduced. T cell responses, especially interferon gamma expression, to mutant SARS-CoV2 spike were significantly reduced compared to those in vaccinees.

Conclusion Strong T cell responses occurred for wildtype and mutant SARS-CoV2 variants, including delta (B.1.617.2), in fully vaccinated individuals, whereas they were partly reduced 1 year after natural infection. Antibody neutralisation of delta mutant was reduced compared to wt, as assessed in a novel inhibition assay with a finger stick drop of blood. Hence, immune responses after vaccination are stronger compared to those after naturally occurring infection, pointing out the need of the vaccine to overcome the pandemic.

Competing Interest Statement

All auithors are employees of ISAR Bioscience, a biotech company

Funding Statement

Bayrische Forschungsstiftung grant # 1438-2020

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This project was submitted for ethical review to and approved by the Bavarian Medical Chamber

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* shared senior authorship

Data Availability

All data are available with the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted September 14, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV2 mutant-specific T cells and neutralizing antibodies after vaccination and up to 1 year after infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV2 mutant-specific T cells and neutralizing antibodies after vaccination and up to 1 year after infection
Jennifer R. Richardson, Ralph Götz, Vanessa Mayr, Martin J. Lohse, Hans-Peter Holthoff, Martin Ungerer
medRxiv 2021.09.07.21262725; doi: https://doi.org/10.1101/2021.09.07.21262725
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV2 mutant-specific T cells and neutralizing antibodies after vaccination and up to 1 year after infection
Jennifer R. Richardson, Ralph Götz, Vanessa Mayr, Martin J. Lohse, Hans-Peter Holthoff, Martin Ungerer
medRxiv 2021.09.07.21262725; doi: https://doi.org/10.1101/2021.09.07.21262725

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Allergy and Immunology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (496)
  • Anesthesia (106)
  • Cardiovascular Medicine (1110)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (275)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (505)
  • Epidemiology (9796)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2327)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1567)
  • Health Policy (737)
  • Health Systems and Quality Improvement (608)
  • Hematology (238)
  • HIV/AIDS (508)
  • Infectious Diseases (except HIV/AIDS) (11669)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2154)
  • Nursing (134)
  • Nutrition (340)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (519)
  • Oncology (1185)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (221)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (314)
  • Pediatrics (699)
  • Pharmacology and Therapeutics (303)
  • Primary Care Research (268)
  • Psychiatry and Clinical Psychology (2195)
  • Public and Global Health (4685)
  • Radiology and Imaging (786)
  • Rehabilitation Medicine and Physical Therapy (458)
  • Respiratory Medicine (625)
  • Rheumatology (276)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (212)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)